SEPTInvestingStart Free
Stocks/DYN/SEC Filings/SCHEDULE 13G Nov 16, 2026

DYN SCHEDULE 13G: SEC filing

Wellington Management Group LLP and affiliated entities

Filed with the SEC on Nov 16, 2026 · accession 0000902219-26-000331

DYN filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 16, 2026. Wellington Management Group LLP and affiliated entities filed a Schedule 13G reporting beneficial ownership of approximately 5.7% of Dyne Therapeutics' common stock as of September 30, 2026. The stock moved -2.7% by the first close after the filing.

Summary of the filing

Wellington Management Group LLP and affiliated entities filed a Schedule 13G reporting beneficial ownership of approximately 5.7% of Dyne Therapeutics' common stock as of September 30, 2026. The filing is a passive investment disclosure, with the filers certifying the securities were not acquired for the purpose of changing or influencing control of the issuer.

For details, click here →

Key details

Shares beneficially owned by Wellington Management Group LLP$10.6M
Shares beneficially owned by Wellington Management Company LLP$10.2M
Filer / beneficial ownerWellington Management Group LLP
Affiliated reporting entityWellington Group Holdings LLP
Affiliated reporting entityWellington Investment Advisors Holdings LLP
Affiliated investment adviserWellington Management Company LLP
Issuer / subject companyDyne Therapeutics, Inc.
Compliance manager, wellington management group llpMatthew Revell

How DYN stock reacted

Close before

$17.16

Nov 13, 2026

First close after

-2.68%

$16.70

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for DYN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DYN?

Click here

Frequently asked questions

What did DYN file with the SEC on Nov 16, 2026?

DYN filed a SCHEDULE 13G (SEC filing). Wellington Management Group LLP and affiliated entities filed a Schedule 13G reporting beneficial ownership of approximately 5.7% of Dyne Therapeutics' common stock as of September 30, 2026. The filing is a passive investment disclosure, with the filers certifying the securities were not acquired for the purpose of changing or influencing control of the issuer.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did DYN stock react to this filing?

DYN closed at $17.16 before the filing and $16.70 on Nov 16, 2026 (-2.68%).

Other DYN SEC filings

  • 8-K · SEC filingNov 5, 2026
  • 10-Q · SEC filingNov 5, 2026
  • 8-K · Fda approvalSep 29, 2026
  • SCHEDULE 13G/A · SEC filingAug 13, 2026
  • SCHEDULE 13G/A · SEC filingAug 13, 2026
  • 8-K · SEC filingJul 29, 2026
  • 10-Q · SEC filingJul 29, 2026
  • 424B5 · Secondary offeringJul 22, 2026
  • 8-K · Secondary offeringJul 22, 2026
  • 424B5 · Secondary offeringJul 21, 2026

Get alerts when DYN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
DYN overviewDYN analysisDYN newsLatest SEC filings
Source: SEC EDGAR filing 0000902219-26-000331. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.